Harbour BioMed, a Cambridge, MA- Rotterdam, The Netherlands and Suzhou, China-based global, clinical-stage biopharmaceutical company, closed a $75 million (€67.4 million approx) Series B+ round of financing.
The round was led by new SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century, which joined existing investors Legend Capital, AdvanTech and GIC Pvt. Ltd.